Korro Bio (NASDAQ: KRRO) unveils KRRO-111 AATD RNA editing data
Rhea-AI Filing Summary
Korro Bio reported a new development candidate, KRRO-111, added to its pipeline for the potential treatment of Alpha-1 Antitrypsin Deficiency (AATD). Preclinical mouse data showed more than 90% editing of the SERPINA1 transcript and about 90% repaired functional AAT protein in plasma.
KRRO-111, a subcutaneously delivered GalNAc‑conjugated oligonucleotide, nearly eliminated active Z‑protein production and drove progressive clearance of pre‑existing liver aggregates in PiZZ mouse models. Korro also reaffirmed its OPERA RNA editing platform strategy and noted $157.1 million in cash, cash equivalents and marketable securities as of March 31, 2026, which it expects to support operations into the second half of 2028.
Positive
- None.
Negative
- None.
Insights
Korro advances KRRO-111 with strong preclinical data and solid cash runway.
Korro Bio formally added KRRO-111 to its pipeline for Alpha-1 Antitrypsin Deficiency. In PiZZ mouse models, the GalNAc-conjugated RNA editing oligo achieved more than 90% SERPINA1 RNA editing and roughly 90% functional M-AAT protein in plasma, indicating efficient target engagement.
The program also showed about 95% reduction in non-inclusion Z-AAT and approximately 69% reduction in inclusion-associated Z-AAT aggregates at day 28 after repeat dosing at 3 mg/kg, suggesting both suppression of mutant protein production and aggregate clearance in vivo.
From a funding standpoint, cash, cash equivalents and marketable securities of $157.1 million as of March 31, 2026 and a stated runway into the second half of 2028 give Korro time to move KRRO-111 and KRRO-121 into and through early clinical development, though ultimate outcomes will depend on human trial results and regulatory interactions.
8-K Event Classification
Key Figures
Key Terms
Alpha-1 Antitrypsin Deficiency medical
Oligonucleotide Promoted Editing of RNA (OPERA) technical
GalNAc-conjugated oligonucleotide technical
Adenosine Deaminase Acting on RNA (ADAR) technical
forward-looking statements regulatory
development candidate financial
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer |
|
||
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On May 19, 2026, Korro Bio, Inc. issued a press release announcing the addition of KRRO-111 for the potential treatment of Alpha-1 Antitrypsin Deficiency to its pipeline of therapeutic programs in development. A copy of the press release is filed as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.
Korro Bio, Inc. also updated its corporate presentation for use in meetings with investors, analysts and others. A copy of certain updated slides is filed as Exhibit 99.2 to this current report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
Press Release issued by Korro Bio, Inc., dated May 19, 2026 |
99.2 |
|
Selected Slides from Corporate Presentation of Korro Bio, Inc., dated May 19, 2026 |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
KORRO BIO, INC. |
|
|
|
|
Date: May 19, 2026 |
By: |
/s/ Ram Aiyar |
|
|
|
|
|
Name: Ram Aiyar |
|
|
Title: President and Chief Executive Officer and Interim Chief Financial Officer |
Exhibit 99.1
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
CAMBRIDGE, Mass., May 19, 2026 – Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the addition of KRRO-111 for the potential treatment of AATD to its pipeline of therapeutic programs in development. KRRO-111 is a proprietary GalNAc-conjugated oligonucleotide that is delivered subcutaneously to the liver cells, where it is engineered to co-opt the hepatocytes’ endogenous Adenosine Deaminase Acting on RNA (ADAR) enzyme and repair a pathogenic single nucleotide variant (SNV) on AAT mRNA to restore production of normal AAT protein. This therapeutic profile along with KRRO-111’s rapid onset of action and titratable dosing to treat this disorder, position the compound as a potential best-in-class candidate.
"The addition of KRRO-111 for AATD to our pipeline of transformative therapeutic candidates is the culmination of extensive and robust pre-clinical optimization, achieving the highest level of SERPINA1 editing reported to date using RNA editing. It appears to be a level of highly specific protein correction that functionally approaches what would be expected from a permanent specific DNA modification, while preserving the inherent safety advantages of working at the RNA level," commented Ram Aiyar, Ph.D., Chief Executive Officer and President of Korro Bio. "For patients living with AATD, this represents a meaningful step toward a therapy designed to address the root cause of their disease. This is an important clinical and corporate development milestone for the Company as it highlights the power of the OPERA platform to generate potential best-in-class genetic medicines for patients suffering from debilitating diseases. As we advance KRRO-111 for the potential treatment of AATD into the clinic alongside KRRO-121 for the potential treatment of hyperammonemia in patients with urea cycle disorders, we are well-capitalized to report clinical data from both programs.”
AATD is a genetic disorder most commonly caused by a single missense mutation (G-to-A) in the SERPINA1 gene. Affected adults experience pulmonary emphysema and/or hepatic cirrhosis, as well as end organ manifestations. Greater than 95% of severe clinical cases of AATD are homozygous for the PiZ mutation (known as the PiZZ genotype). There are an estimated 3.4 million individuals with deficiency allele combinations worldwide. The only current FDA-approved treatment for AATD is augmentation therapy, a once-weekly infusion of pooled human plasma-derived AAT protein, which does not adequately address the manifestations of AATD.
In preclinical studies, KRRO-111 demonstrated best-in-class RNA editing where >90% of the AAT transcripts in the liver cells have been corrected, translating into ~90% M-AAT protein. In a repeat-dose study, KRRO-111 (3 mg/kg) was administered to PiZZ mice with a loading phase followed by dosing once every two weeks. KRRO-111 nearly eliminated active Z protein production, reducing non-inclusion Z-AAT by ~95% versus vehicle at both days 28 and 56, reflecting near-complete cessation of Z protein synthesis across the hepatocyte population. Pre-existing aggregates were progressively cleared, with inclusion-associated Z-AAT significantly reduced by approximately 69% at day 28, consistent with autophagic clearance of accumulated protein following successful editing; the residual burden reflects pre-existing disease rather than incomplete editing. By simultaneously increasing circulating M-AAT protein and decreasing pathogenic Z-AAT aggregates in the lung, KRRO-111 has the potential to improve both lung and liver manifestations of the disease.
The Company plans to present additional data from its KRRO-111 program at a future scientific meeting or Company-hosted event.
About Korro
Korro is a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases. OPERA provides precise, tissue-directed delivery of oligonucleotides that modify the targeted native mRNA transcript to repair or form a de-novo protein with enhanced functionality. The platform combines a suite of capabilities consisting of sophisticated knowledge of transcription biology through ADAR proteins (Adenosine Deaminases Acting on RNA), machine learning optimization of oligonucleotides, linker chemistry expertise, along with use of a highly targeted tissue-specific delivery methodology. As such, the OPERA platform has enabled Korro to generate and advance a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, providing precise yet transient single base edits to produce therapeutic proteins with augmented activity versus its endogenous counterpart. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary OPERA platform with precedented delivery modalities, including N-acetylgalactosamine (GalNAc) conjugated for delivery for subcutaneous administration, manufacturing know-how, and established regulatory pathways of approved oligonucleotide medicines. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.
Korro intends to use its Investor Relations website, LinkedIn, and X (Twitter) as means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Korro’s Investor Relations website and follow @KorroBio on LinkedIn, and X (Twitter), in addition to following Korro’s press releases, SEC filings, public conference calls, presentations, and webcasts.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, but are not limited to, express or implied statements regarding expectations, hopes, beliefs, intentions or strategies of Korro regarding the future including, without limitation, express or implied statements regarding: the best-in-class potential of, and market opportunity for, KRRO-111 as a treatment for AATD; KRRO-111’s ability to achieve the functional equivalent of a DNA modification without altering the genome; Korro’s cash runway and financial resources; the therapeutic potential of the OPERA platform; and reaching and reporting clinical milestones for KRRO-121 and KRRO-111; among others. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would,” “aim,” “target,”
“commit,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking. Forward-looking statements are based on current expectations and assumptions that, while considered reasonable are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management’s control including risks associated with pre-clinical studies and conducting clinical trials; risks associated with validating in clinical trials observations from pre-clinical studies; risks associated with collaborating with third parties; other risks associated with protecting intellectual property; as well as risks associated with general economic conditions; and other risks and uncertainties indicated from time to time in Korro’s filings with the Securities and Exchange Commission (SEC), including under the caption “Risk Factors” in Korro’s Quarterly Report on Form 10-Q or Annual Report on Form 10-K, as such may be amended or supplemented by its other filings with the SEC. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Except as required by law, Korro does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or in the events, conditions or circumstances on which any such statement is based. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in Korro.
Korro Bio Contact Information
Investor & Media Contact
Malini Chatterjee, Ph.D.
Blueprint Life Science Group
mchatterjee@bplifescience.com or ir@korrobio.com
917.330.4269
May 2026 Corporate Presentation Exhibit 99.2
Forward-Looking Statement and Disclaimers CONFIDENTIAL Forward-Looking Statements Certain statements in this presentation may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, but are not limited to, express or implied statements regarding expectations, hopes, beliefs, intentions or strategies of Korro Bio, Inc. (Korro) regarding the future including, without limitation, express or implied statements regarding: Korro’s ability to activate a biological pathways with RNA editing; Korro’s ability to create value in 2026 and beyond; Korro’s cash runway and uses thereof; the timing of updates on Korro's assets; the timing of and ability to submit a regulatory filing for KRRO-121; the market opportunity for KRRO-121; KRRO-121’s pan-urea cycle disorder (UCD) potential; KRRO-121’s first-in-class potential as a treatment for ammonia control; KRRO-121’s blockbuster potential in multiple indications; KRRO-111's best-in-class potential as a treatment for Alpha-1 Antitrypsin Deficiency (AATD); and timing of nominating development candidate for Korro’s third GalNAC-conjugated liver asset; among others. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “aim,” “anticipate,” “believe,” “commit,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “target,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking. Forward-looking statements are based on current expectations and assumptions that, while considered reasonable are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management’s control including risks inherent in biopharmaceutical development; risks associated with pre-clinical studies and clinical trials; and other risks associated with obtaining regulatory approvals and protecting intellectual property; as well as risks associated with general economic conditions; the possibility that Korro may be adversely affected by other economic, business, and/or competitive factors; other risks and uncertainties indicated from time to time in Korro’s filings with the SEC, including under the caption “Risk Factors” in Korro’s most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the SEC, as such may be amended or supplemented by its other filings with the SEC. Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this presentation, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Except as required by law, Korro does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or in the events, conditions or circumstances on which any such statement is based. This presentation does not purport to summarize all of the conditions, risks and other attributes of an investment in Korro. Industry and Market Data Certain information contained in this presentation relates to or is based on studies, publications, surveys and Korro’s own internal estimates and research. In this presentation, Korro relies on, and refers to, publicly available information and statistics regarding market participants in the sector in which Korro competes and other industry data. Any comparison of Korro to any other entity assumes the reliability of the information available to Korro. Korro obtained this information and statistics from third-party sources, including reports by market research firms and company filings. In addition, all of the market data included in this presentation involve a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while Korro believes its internal research is reliable, such research has not been verified by any independent source and Korro has not independently verified the information. Trademarks This presentation may contain trademarks, service marks, trade names and copyrights of Korro or other third parties, which are the property of their respective owners. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this presentation may be listed without the TM, SM © or ® symbols, but Korro will assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to its trademarks, service marks, trade names and copyrights.
Positioned for Value Creation in 2026 and Beyond KRRO-111 Development Candidate (DC) nominated for GalNAc-conjugated alpha-1 antitrypsin deficiency (AATD) program Regulatory filing for KRRO-121 anticipated in H2 2026 DC expected for a 3rd GalNAc-conjugated liver asset in H2 2026 Cash runway into H2 ‘28 enabling multiple milestones 1 Potential for partnership across our pipeline Cash, cash equivalents and marketable securities of $157.1 million as of March 31, 2026
KRRO-111, a GalNAc-conjugated RNA Editing Oligo, Demonstrated >90% Editing and ~90% M-AAT Protein In Vivo 0 1 Week SC Day 7: sample collection Dosing: Q2Dx3 at 5 or 10 mg/kg NSG-PiZ Mouse GalNAc % M-AAT Protein SERPINA1 RNA Editing Note: Subcutaneous dosing Q2Dx3 at 5 or 10 mg/kg for each dose; editing efficiency and protein percentage are measured on day 7 by NGS and LC/MS, respectively. Proportion of M-AAT was calculated from the sum of M-AAT and Z-AAT detected in serum. KRRO-111
KRRO-111 Nearly Eliminates Active Z Protein Production and Drives Progressive Clearance of Pre-existing Aggregates In Vivo INCLUSION-ASSOCIATED Z-AAT Pre-existing aggregates · autophagic clearance Vehicle Control KRRO-111 Z-AAT protein (brown) Non-inclusion Z-AAT (blue) Inclusion-associated Z-AAT (red) Robust Reduction of Pre-Existing Z-AAT Aggregates Elimination of Active Z-AAT Protein Production and Progressive Clearance of Pre-existing Aggregates IHC: immunohistochemistry, 140X, Day 56 representative images, Z-AAT: homozygous Z-variant AAT Study design: Q2Dx3, Q2Wx4: every two weeks in C57BL/6-PiZZ mice, dose = 3mg/kg NON-INCLUSION Z-AAT Active Z protein · editing efficacy Near-Complete Cessation of Z-AAT Protein Synthesis